NCT05328778CompletedPhase 4
Pharmacokinetics and Pharmacodynamics of Sugammadex Dosed by Corrected Body Weight for Reversal of Vecuronium in Obese Patients
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to illustrate pharmacokinetics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in patients during laparoscopic surgery
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 4 Mar 2022
- Start date
- 14 Apr 2022
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Guangzhou General Hospital of Guangzhou Military Command
- Diseases
- Obesity
- NCT number
- NCT05328778
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 48
- From 14 Apr 2022 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Drugs that react with rocuronium and vecuronium were taken
Other illness
- Neuromuscular diseases
- Malignant hyperthermia or allergic history during general anesthesia
Other
- Pregnant or lactating women
Who the study is looking for
- ASA: Ⅰ\~Ⅲ
- BMI≥25kg/m²
- Patients receiving bariatric surgery.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guangzhou Military Region General Hospital, Department of Anesthesiology Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.